Drug Profile
Research programme: QseC antagonists - OMM Scientific
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Omm Scientific
- Developer National Institute of Allergy and Infectious Diseases; Omm Scientific
- Class Antibacterials
- Mechanism of Action Escherichia coli protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Gram-negative-infections in USA
- 04 Aug 2016 Research programme: QseC antagonists - OMM Scientific is available for licensing as of 04 Aug 2016. http://www.ommscientific.com/overview.html
- 03 Aug 2016 Preclinical trials in Gram-negative infections in USA (unspecified route)